Santo, L., Hideshima, T., Kung, A. L., Tseng, J., Tamang, D., Yang, M., . . . Raje, N. (2012). Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. American Society of Hematology.
Citação norma ChicagoSanto, Loredana, et al. Preclinical Activity, Pharmacodynamic, and Pharmacokinetic Properties of a Selective HDAC6 Inhibitor, ACY-1215, in Combination With Bortezomib in Multiple Myeloma. American Society of Hematology, 2012.
Citação norma MLASanto, Loredana, et al. Preclinical Activity, Pharmacodynamic, and Pharmacokinetic Properties of a Selective HDAC6 Inhibitor, ACY-1215, in Combination With Bortezomib in Multiple Myeloma. American Society of Hematology, 2012.